Transparency Guidelines
COVID-19
Who We Are
Our Industry
Resources
Login
Resources
Submissions
See all
Medsafe Consultation: Medsafe Fees Review
PHARMAC Consultation: Revised Terms of Reference for CAC, PTAC and PTAC Sub-Committees and Associated PHARMAC Discussions document
Medsafe Consultation: Plan to update the New Zealand Code of Good Manufacturing Practice
PHARMAC Consultation: Proposal (dated 1 Oct 2020) to decline inactive funding applications 30 October 2020
Medsafe Consultation: Revisions to Part 10 of the GRTPNZ
PHARMAC Consultation: Proposal to modify PHARMAC’s approach to competitive procurement
Medsafe Consultation: Revisions to Part 8 of the GRTPNZ
Medsafe Consultation: Proposed Warning Statement for Substances in Medicines
Publications
See all
Educational Whitepaper: Towards Best Practice in Consumer Involvement in Decisions about Funding Medicines in New Zealand
New Zealand's Medicines Landscape 2020/21
Public Perceptions of Healthcare, Pharmaceuticals and COVID-19 in New Zealand Key Findings of two National Online Surveys April 2021
Funding Medicines in New Zealand: Revision of the Medicines Waiting List to 30 April 2020
New Zealand's Medicines Landscape 2019/20
Public Perceptions of Medicines Funding in New Zealand - Key Findings of two National Online Surveys
Access to Medicines (AtoM 2) Report 2020
NZIER A new generation medicines policy - discussion document
Media Releases
See all
Boring Budget 2021 reinforces two tier medicines access system in New Zealand
Medicines New Zealand supportive of Government’s PHARMAC Review assuming it is not a box-ticking exercise
Medicines New Zealand and the New Zealand Medical Association launch Transparency Initiative
EU export restrictions on COVID-19 vaccines may jeopardise global supply
PHARMAC Inquiry: “nothing should be off the table”
Collaborative Consultation on Medicines Policy Closes
Solutions for the Future: A New Medicines Landscape
It’s time to put fairness into focus
